← FDA DRUG APPROVALS

FDA ANDA · ANDA210762

FENTANYL CITRATE

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA210762
TYPE
ANDA
ORIGINAL APPROVAL
2019-05-03
LATEST ACTION
2025-04-24
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

FENTANYL CITRATE PRESERVATIVE FREEPrescription
FENTANYL CITRATE EQ 0.05MG BASE/ML · INJECTABLE · INJECTION

Approval history

2025-04-24Labeling · Supplement 8 · standardAP
2025-04-24Labeling · Supplement 6 · standardAP
2025-04-24Labeling · Supplement 7 · standardAP
2020-05-07Labeling · Supplement 1 · standardAP
2019-05-03UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →